Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

TESARO, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-03-01

Employees: 715

Market Cap: -

Website: http://tesarobio.com

Clinical Trials

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: Niraparib
Biological: TSR-042 (Dostarlimab)
Biological: Pembrolizumab

First Posted Date: 2017-10-13

Last Posted Date: 2023-10-16

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 53

Registration Number: NCT03308942

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
Non Small Cell Lung Cancer Stage IIIB
Neoplasms
Solid Tumor
Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Metastatic Cancer

Interventions: Drug: Niraparib
Drug: TSR-042
Drug: Carboplatin-Paclitaxel
Drug: Carboplatin-Pemetrexed
Drug: TSR-022
Drug: Bevacizumab
Drug: Carboplatin-Nab-Paclitaxel

First Posted Date: 2017-10-12

Last Posted Date: 2024-05-29

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 58

Registration Number: NCT03307785

Locations: 🇺🇸
GSK Investigational Site, San Marcos, Texas, United States

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: TSR-033
Drug: Dostarlimab
Drug: FOLFIRI
Drug: mFOLFOX6
Drug: Bevacizumab

First Posted Date: 2017-08-16

Last Posted Date: 2024-04-11

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 111

Registration Number: NCT03250832

Locations: 🇫🇷
GSK Investigational Site, Villejuif cedex, France

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Conditions: Recurrent Ovarian Cancer

First Posted Date: 2017-01-20

Last Posted Date: 2017-04-17

Lead Sponsor: Tesaro, Inc.

Registration Number: NCT03025867

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: TSR-022
Drug: TSR-042
Drug: Nivolumab
Drug: TSR-033
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-06-29

Last Posted Date: 2024-06-20

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 447

Registration Number: NCT02817633

Locations: 🇨🇳
GSK Investigational Site, Tainan, Taiwan

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Biological: Dostarlimab

First Posted Date: 2016-03-22

Last Posted Date: 2025-03-03

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 740

Registration Number: NCT02715284

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Phase 1

Completed

Conditions: Triple Negative Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Neoplasms
Advanced Breast Cancer
Ovarian Cancer
Stage IV Breast Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: niraparib
Biological: pembrolizumab

First Posted Date: 2016-01-18

Last Posted Date: 2022-12-01

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 122

Registration Number: NCT02657889

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Ovarian Neoplasms

Interventions: Drug: Niraparib
Drug: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2025-06-15

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 733

Registration Number: NCT02655016

Locations: 🇬🇧
GSK Investigational Site, Truro, United Kingdom

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Niraparib IV (Labeled)
Drug: Niraparib Oral Capsules (Labeled)
Drug: Niraparib Oral Capsules (Unlabeled)

First Posted Date: 2015-06-19

Last Posted Date: 2020-01-13

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 12

Registration Number: NCT02476552

Locations: 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Phase 1

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Rolapitant
Drug: Cooperstown Cocktail
Drug: Digoxin
Drug: Sulfasalazine

First Posted Date: 2015-05-05

Last Posted Date: 2015-08-25

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 102

Registration Number: NCT02434861

Locations: 🇺🇸
Parexel Early Phase Unit, Baltimor, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy